Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22510634 | 0.80 | CYP19A1 (0.82) | CYP19A1NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL11521784 | 0.77 | CYP19A1 (0.61) | CYP19A1NPC1RAB9AHRH4ALDH1A1 | |
| SCHEMBL9290483 | 0.77 | CYP19A1 (0.61) | CYP19A1NPC1RAB9AHRH4ALDH1A1 | |
| SCHEMBL16717478 | 0.77 | CYP19A1 (0.61) | CYP19A1NPC1RAB9AHRH4ALDH1A1 | |
| SCHEMBL16401451 | 0.77 | CYP19A1 (0.61) | CYP19A1NPC1RAB9AHRH4HSP90AB1 | |
| SCHEMBL16864593 | 0.77 | CYP19A1 (0.61) | CYP19A1NPC1RAB9AHRH4ALDH1A1 | |
| SCHEMBL1242192 | 0.77 | CYP19A1 (0.61) | CYP19A1NPC1RAB9AHRH4ALDH1A1 | |
| SCHEMBL15836586 | 0.76 | CYP19A1 (0.93) | CYP19A1NPC1RAB9AFLT3GSK3B | |
| SCHEMBL12022159 | 0.76 | KCNMA1 (0.69) | CYP19A1NPC1RAB9AHRH4HSP90AB1 | |
| SCHEMBL935182 | 0.76 | CYP19A1 (1.00) | CYP19A1NPC1RAB9AFLT3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130272961-A1 | RADIOIODINATED GUANIDINES | GE HEALTHCARE LIMITED (GB) | 2013-10-17 | — | — | US | disclosed |
| US-20130272960-A1 | RADIOIODINATED FATTY ACIDS | GE HEALTHCARE LIMITED (GB) | 2013-10-17 | — | — | US | disclosed |
| US-20120251447-A1 | RADIOIODINATED TROPANE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| US-20120134923-A1 | RADIOIODINATION METHOD | GE HEALTHCARE LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130272960-A1 | RADIOIODINATED FATTY ACIDS | FFAR3, FFAR1, FFAR2 | CYP19A1 533/4885NPC1 134/4885RAB9A 1311/4885 |
| US-20120251447-A1 | RADIOIODINATED TROPANE DERIVATIVES | ADRB3, TH, TBXA2R | CYP19A1 79/4885NPC1 764/4885RAB9A 3162/4885 |
| US-20130272961-A1 | RADIOIODINATED GUANIDINES | GUCY1B2, GUCY1A2, GMPS | CYP19A1 2805/4885NPC1 431/4885RAB9A 424/4885 |
| US-20120134923-A1 | RADIOIODINATION METHOD | BTD, BTF3, BTN3A1 | CYP19A1 682/4885NPC1 1035/4885RAB9A 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.